KLRS · Kalaris Therapeutics, Inc.
$3.39
+0.05 (+1.50%)
At close · Jul 29
Market Cap
$79.47M
Shares
23.79M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.34
Open$3.60
Day$3.28–3.69
52W$2.14–11.88
Avg vol 30d461K
Short int520K · 2.2% float · 11.7d
Short vol63%
Last earningsFeb 15, 2023
DataJul 2020–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−49%
below
Price vs 50-day avg
−26%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
12%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−23%
trailing
6-month return
−63%
trailing
YTD return
−60%
this year
Relative strength
−71%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Distributing
4 of 58 funds reported for Jun 30 · net -79.5K sh shares
Insider flow
Accumulating
Net +$1.2M over 90 days · 0% sells
Short interest
Rising
2.19% of float · ▲ +3.5% MoM · 11.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
58 holders — near 1-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
EPS growth
+94%
Y/Y
Free cash flow
$-38.6M
Balance sheet
$98.1M
net cash
Quant / Vol
risk profile
Volatility
111%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
13.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−49%
Bearish
Price vs 50-day avg
−26%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
12%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Distributing
4 of 58 funds reported for Jun 30 · net -79.5K sh shares
Insider flow
Accumulating
Net +$1.2M over 90 days · 0% sells
Short interest
Rising
2.19% of float · ▲ +3.5% MoM · 11.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
58 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $3 · 12%
52-wk high $12
vs 200-day avg -49%
vs 50-day avg -26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KLRS
this stock
Kalaris Therapeutics, Inc.
|
$79.47M | -60.4% | — | — | 2.2% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KLRS | -16.5% | -22.7% | -63.3% | -17.9% | -60.4% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -15.5% | -22.7% | -70.8% | -17.2% | -69.1% |